Evidence map›Paper›PMID 23028424›Full record

ArticlePloS one2012

Proteomic and systems biology analysis of monocytes exposed to securinine, a GABA(A) receptor antagonist and immune adjuvant.

Matt Shipman, Kirk Lubick, David Fouchard, Rajani Guram, Paul Grieco, Mark Jutila, Edward A Dratz

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Molecular Mechanisms of Medicinal PlantCurrent pharmaceutical design · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Matt ShipmanDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, Montana, United States of America. mshipman@chemistry.montana.edu
Kirk Lubick
David Fouchard
Rajani Guram
Paul Grieco
Mark Jutila
Edward A Dratz
Montana State University · US

Funding

SYSTEMS BIOLOGY OF HOST-PATHOGEN INTERACTIONSP20RR024237 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI SINGEL, DAVID J · 2008 to 2011
$8.1M
Multiplex Fluorescent Dyes for Ultrasensitive ProteomicsR42RR021790 · NCRR · ZDYE, LLC · PI DRATZ, EDWARD A · 2008 to 2010
$1.1M
NCRR NIH HHS #1P20RR024237NCRR NIH HHS #2R42RR021790A1NCRR NIH HHS P20 RR024237NCRR NIH HHS R42 RR021790
6 · The paper itself

Abstract

Securinine, a GABA(A) receptor antagonist, has been reported to enhance monocyte cell killing of Coxiella burnetii without obvious adverse effects in vivo. We employed multiplex 2D gel electrophoresis using Zdyes, a new generation of covalently linked fluorescent differential protein detection dyes to analyze changes in the monocyte proteome in response to Securinine. Securinine antagonism of GABA(A) receptors triggers the activation of p38. We used the differential protein expression results to guide a search of the literature and network analysis software to construct a systems biology model of the effect of Securinine on monocytes. The model suggests that various metabolic modulators (fatty acid binding protein 5, inosine 5'-monophosphate dehydrogenase, and thioredoxin) are at least partially reshaping the metabolic landscape within the monocytes. The actin bundling protein L-plastin, and the Ca(2+) binding protein S100A4 also appear to have important roles in the immune response stimulated by Securinine. Fatty acid binding protein 5 (FABP5) may be involved in effecting lipid raft composition, inflammation, and hormonal regulation of monocytes, and the model suggests that FABP5 may be a central regulator of metabolism in activated monocytes. The model also suggests that the heat shock proteins have a significant impact on the monocyte immune response. The model provides a framework to guide future investigations into the mechanisms of Securinine action and with elaboration may help guide development of new types of immune adjuvants.

Indexed as

ProteomeAdjuvants, ImmunologicAntigen PresentationAzepinesComputational BiologyElectrophoresis, Gel, Two-DimensionalGABA-A Receptor AntagonistsHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Bridged-RingHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsLactonesMetabolic Networks and PathwaysModels, BiologicalMonocytesp38 Mitogen-Activated Protein KinasesAdjuvants, ImmunologicAzepinesGABA-A Receptor AntagonistsHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Bridged-RingHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsLactonesp38 Mitogen-Activated Protein KinasesPiperidinesProteomeReceptors, GABA-Asecurinine

Identifiers

PMID23028424
PMCPMC3441550
OpenAlexW2031872805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.